Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigexole vs Neupro Adhesiveness in Parkinson's Disease
NCT07015346Not yet recruiting
- Sponsor
- EVA Pharma
- Start
- Sep 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of rotigotine in Parkinson's disease (PD) (2 arms), sponsored by EVA Pharma. Primary endpoint: Cumulative mean percentage adhesion of the transdermal patch over the 24-hour dosing interval. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07015346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015346.